Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, non-randomized study to evaluate the efficacy and safety of BAY94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral beta-amyloid when compared to postmortem histopathology

Next Previous
Trial Profile

An open-label, non-randomized study to evaluate the efficacy and safety of BAY94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral beta-amyloid when compared to postmortem histopathology

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Registrational
  • Sponsors Bayer; Bayer HealthCare; Life Molecular Imaging

Most Recent Events

  • 13 Dec 2023 According to Life Molecular Imaging, company announced that the Japanese Ministry of Health has approved the reimbursement by governmental health insurance of the amyloid Positron Emission Tomography (PET) diagnostic Neuraceq.
  • 31 Aug 2015 According to a Piramal Imaging media release, data from this study were published in the current issue of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
  • 08 Jun 2015 According to Piramal Imaging media release, results were presented at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top